Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intra-atrial defibrillation in humans.

B Lüderitz1, W Jung

  • 1Department of Medicine-Cardiology, University of Bonn, Germany. med-c-p@uni-bonn.de

The Thoracic and Cardiovascular Surgeon
|October 16, 1999
PubMed
Summary

Atrial fibrillation is a common heart rhythm disorder that places a significant burden on healthcare systems. This article reviews the potential for implantable devices that deliver internal electrical shocks to restore normal heart rhythm. While early evidence suggests this approach is feasible, researchers must overcome challenges related to patient discomfort and the risk of triggering dangerous heart rhythms. Future progress depends on evaluating clinical success, patient quality of life, and overall cost-effectiveness. Combining rhythm detection and treatment for both upper and lower heart chambers could offer a major advancement in managing complex arrhythmias.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of obstructive sleep apnea on heart rate turbulence.

Basic research in cardiology·2005
Same author

[Postoperative arrhythmias].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

[Atrial fibrillation -- interventional therapy with respect to age].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein.

Heart (British Cardiac Society)·2005
Same author

Atrial fibrillation: profit from cardiac pacing?

Zeitschrift fur Kardiologie·2005
Same author

[Progressive upper lobe consolidation in a 73-year old healthy woman].

Der Internist·2005

Area of Science:

  • Cardiovascular medicine and intra-atrial defibrillation research
  • Electrophysiology and clinical cardiology

Background:

Atrial fibrillation remains a persistent clinical challenge due to its high prevalence and substantial economic burden on global healthcare systems. Prior research has shown that current pharmacological interventions often fail to maintain sinus rhythm in many patients. This gap motivated the development of nonpharmacological strategies, including the use of implantable devices for rhythm restoration. It was already known that internal electrical stimulation can successfully terminate atrial arrhythmias in both animal models and human subjects. That uncertainty drove investigations into the safety profiles of these devices during clinical application. No prior work had resolved the specific concerns regarding patient pain perception during shock delivery. Researchers also identified a potential risk of inducing dangerous ventricular arrhythmias when applying low-energy discharges. These combined factors highlight the necessity for rigorous evaluation before widespread adoption of this technology becomes feasible.

Purpose Of The Study:

Keywords:
cardiac electrophysiologyimplantable devicestachyarrhythmia treatmentsinus rhythm restoration

Frequently Asked Questions

The researchers propose that this system functions by delivering low-energy electrical discharges directly to the atrium to terminate fibrillation. This mechanism aims to restore normal sinus rhythm while minimizing the risks associated with traditional high-energy external cardioversion.

The authors describe a physician-activated device as the initial prototype for this therapy. This tool is designed to allow controlled intervention for patients who do not respond to standard pharmacological treatments.

The researchers emphasize that restricting use to highly selected patients is necessary to manage safety risks. This condition ensures that individuals with drug-refractory and poorly tolerated episodes receive the intervention under controlled clinical supervision.

Related Experiment Videos

The aim of this review is to evaluate the current status and future potential of internal electrical therapy for atrial fibrillation. This study addresses the significant challenges associated with nonpharmacological management of this common heart rhythm disorder. The authors seek to define the criteria for patient selection in the early stages of device implementation. This work explores the necessity of balancing clinical efficacy with patient comfort and safety. The motivation for this research stems from the high economic impact of atrial fibrillation on healthcare systems. The team investigates the requirements for demonstrating the benefit of this therapy relative to existing treatment options. This article provides a synthesis of evidence regarding the feasibility of internal shock delivery. The researchers intend to outline the milestones required for advancing arrhythmia management systems in clinical practice.

Main Methods:

Review approach involved synthesizing existing evidence from both animal and human clinical investigations. The authors evaluated the feasibility of internal electrical stimulation for rhythm correction. This analysis focused on identifying major barriers to the widespread adoption of implantable devices. The team examined data regarding the safety of low-energy shock delivery in the cardiac environment. Investigators assessed the current limitations of nonpharmacological interventions for recurrent heart rhythm disorders. The study design prioritized the identification of patient selection criteria for initial device testing. Researchers reviewed the requirements for future cost-effectiveness and quality of life assessments. This methodology provided a framework for understanding the potential integration of detection and treatment systems.

Main Results:

Key findings from the literature indicate that internal electrical stimulation is a feasible method for terminating atrial arrhythmias. Studies have demonstrated that this approach can be performed safely in both animal and human subjects. The primary concern identified is the level of pain experienced by patients during the delivery of electrical shocks. Another significant finding is the potential risk of triggering life-threatening ventricular arrhythmias during low-energy discharge. The authors report that current device prototypes are designed for physician-activated use in specific clinical scenarios. Evidence suggests that initial therapy should be limited to patients with drug-refractory and poorly tolerated conditions. The literature highlights that the success of this therapy depends on clinical efficacy and patient tolerance. Researchers note that future studies must establish the benefit of this technology compared to other available management strategies.

Conclusions:

The authors suggest that initial implementation of this technology should target patients with drug-refractory and poorly tolerated recurrent episodes. Future expansion of this therapeutic option depends heavily on demonstrating consistent clinical efficacy and safety profiles. Patient tolerance remains a primary metric for determining the long-term viability of this intervention. Synthesis and implications indicate that comprehensive assessments of quality of life are required to justify this approach. Researchers propose that cost-effectiveness analyses will be necessary to compare this device against existing management strategies. The team highlights that integrating detection and treatment for both atrial and ventricular chambers could represent a significant milestone. This advancement might improve outcomes for individuals suffering from multiple types of tachyarrhythmias. The evidence supports a cautious, staged approach to integrating these systems into standard clinical practice.

The authors suggest that data regarding patient tolerance and clinical safety will dictate the future expansion of this therapy. These metrics are used to evaluate whether the device provides a meaningful benefit over existing management options.

The researchers identify pain perception during shock delivery as a significant measurement of patient experience. This phenomenon is compared against the clinical efficacy of the device to determine if the therapy is acceptable for long-term use.

The authors propose that integrating detection and treatment for both chambers could represent a major milestone in arrhythmia management. This implication suggests that combined systems may offer superior outcomes compared to devices that only treat the atrium.